{"id":"estriol-succinate","rwe":[{"pmid":"7641124","year":"1995","title":"Efficacy and safety of estriol replacement therapy for climacteric women.","finding":"","journal":"Zhonghua yi xue za zhi = Chinese medical journal; Free China ed","studyType":"Clinical Study"},{"pmid":"7991851","year":"1993","title":"[Cytologic response of the irradiated vagina to estriol succinate].","finding":"","journal":"Revista chilena de obstetricia y ginecologia","studyType":"Clinical Study"},{"pmid":"2346078","year":"1990","title":"The effect of peroral lynestrenol on serum lipids and lipoproteins in therapeutic amenorrhea of mentally retarded women.","finding":"","journal":"Acta obstetricia et gynecologica Scandinavica","studyType":"Clinical Study"},{"pmid":"3428874","year":"1987","title":"Results of a 5 years prospective study of estriol succinate treatment in patients with climacteric complaints.","finding":"","journal":"Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","studyType":"Clinical Study"},{"pmid":"6832445","year":"1983","title":"The effect of oral estriol succinate therapy on the endometrial morphology in postmenopausal women: the significance of fractionation of the dose.","finding":"","journal":"European journal of obstetrics, gynecology, and reproductive biology","studyType":"Clinical Study"}],"tags":[{"label":"estriol succinate","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Estrogen receptor beta","category":"target"},{"label":"ESR2","category":"gene"},{"label":"ESR1","category":"gene"},{"label":"SHBG","category":"gene"},{"label":"Active","category":"status"}],"phase":"unknown","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"stiptanon","offLabel":[],"synonyms":["succinylestriol","estriol succinate sodium","estriol succinate disodium","estriol succinate disodium salt","estriol succinate","stiptanon"],"timeline":[],"approvals":[],"brandName":"Stiptanon","ecosystem":[],"mechanism":{"target":"Corticosteroid-binding globulin, Olfactory receptor 51E2, Alpha-synuclein","targets":[{"gene":"ESR2","source":"DrugCentral","target":"Estrogen receptor beta","protein":"Estrogen receptor beta"},{"gene":"ESR1","source":"DrugCentral","target":"Estrogen receptor","protein":"Estrogen receptor"},{"gene":"SHBG","source":"DrugCentral","target":"Sex hormone-binding globulin","protein":"Sex hormone-binding globulin"},{"gene":"SLC6A4","source":"DrugCentral","target":"Sodium-dependent serotonin transporter","protein":"Sodium-dependent serotonin transporter"},{"gene":"SERPINA6","source":"DrugCentral","target":"Corticosteroid-binding globulin","protein":"Corticosteroid-binding globulin"},{"gene":"NR3C1","source":"DrugCentral","target":"Glucocorticoid receptor","protein":"Glucocorticoid receptor"},{"gene":"SNCA","source":"DrugCentral","target":"Alpha-synuclein","protein":"Alpha-synuclein"},{"gene":"OR51E2","source":"DrugCentral","target":"Olfactory receptor 51E2","protein":"Olfactory receptor 51E2"}],"modality":"Small Molecule","drugClass":"estriol succinate","explanation":"Think of estrogen receptors like locks on a door. Estriol succinate, or Stiptanon, is a key that fits into these locks, specifically the beta subtype. When it binds, it can turn on or off certain genes that control how cells grow and function.","oneSentence":"Stiptanon works by binding to estrogen receptors, specifically the beta subtype, to exert its effects.","technicalDetail":"Estriol succinate acts as a selective estrogen receptor modulator (SERM) by binding to estrogen receptor beta (ERβ) with high affinity, potentially influencing gene expression and cellular function."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Estriol_succinate","title":"Estriol succinate","extract":"Estriol succinate, sold under the brand name Synapause among others, is an estrogen medication which is used in the treatment of menopausal symptoms. It is taken by mouth, in through the vagina, and by injection.","wiki_history":"==History==\nEstriol succinate was introduced for medical use in 1966.","wiki_society_and_culture":"==Society and culture==\n\n===Generic names===\nEstriol succinate is the generic name of the drug and its  and . Other synonyms include oestriol succinate, estriol disuccinate, and estriol hemisuccinate. When provided as the sodium salt, estriol succinate is known as estriol sodium succinate () or as oestriol sodium succinate.\n\n===Brand names===\nEstriol succinate has been marketed under brand names including Blissel, Evalon, Gelistrol, Hemostyptanon, Orgastyptin, Ovestin, Sinapause, Styptanon, Synapsa, Synapasa, Synapausa, and Synapause, among others. Estriol sodium succinate has been marketed specifically under the brand names Pausan and Styptanon.\n\n===Availability===\nEstriol succinate is or has been marketed in Europe, Hong Kong, and Mexico."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1067","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=estriol%20succinate","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=estriol succinate","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Estriol_succinate","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T11:04:56.989291","biosimilars":[],"competitors":[{"drugName":"cortisone acetate","drugSlug":"cortisone-acetate","fdaApproval":"1950-06-13","genericCount":12,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"estradiol","drugSlug":"estradiol","fdaApproval":"1975-07-23","patentExpiry":"Nov 21, 2032","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"estradiol cypionate","drugSlug":"estradiol-cypionate","fdaApproval":"1979-08-15","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"estriol","drugSlug":"estriol","fdaApproval":"","relationship":"same-target"},{"drugName":"estrone","drugSlug":"estrone","fdaApproval":"1979-02-21","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"hydrocortisone","drugSlug":"hydrocortisone","fdaApproval":"1952-08-05","patentExpiry":"Nov 19, 2032","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"hydrocortisone acetate","drugSlug":"hydrocortisone-acetate","fdaApproval":"1951-12-21","genericCount":14,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"hydroxyprogesterone caproate","drugSlug":"hydroxyprogesterone-caproate","fdaApproval":"1975-10-03","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"nandrolone decanoate","drugSlug":"nandrolone-decanoate","fdaApproval":"1962-10-05","genericCount":4,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"prasterone","drugSlug":"prasterone","fdaApproval":"","patentExpiry":"Mar 19, 2031","patentStatus":"Patent protected","relationship":"same-target"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"estriol succinate","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"cortisone-acetate","brandName":"cortisone acetate","genericName":"cortisone acetate","approvalYear":"1950","relationship":"same-target"},{"drugId":"estradiol","brandName":"estradiol","genericName":"estradiol","approvalYear":"1975","relationship":"same-target"},{"drugId":"estradiol-cypionate","brandName":"estradiol cypionate","genericName":"estradiol cypionate","approvalYear":"1979","relationship":"same-target"},{"drugId":"estriol","brandName":"estriol","genericName":"estriol","approvalYear":"","relationship":"same-target"},{"drugId":"estrone","brandName":"estrone","genericName":"estrone","approvalYear":"1979","relationship":"same-target"},{"drugId":"hydrocortisone","brandName":"hydrocortisone","genericName":"hydrocortisone","approvalYear":"1952","relationship":"same-target"},{"drugId":"hydrocortisone-acetate","brandName":"hydrocortisone acetate","genericName":"hydrocortisone acetate","approvalYear":"1951","relationship":"same-target"},{"drugId":"hydroxyprogesterone-caproate","brandName":"hydroxyprogesterone caproate","genericName":"hydroxyprogesterone caproate","approvalYear":"1975","relationship":"same-target"},{"drugId":"nandrolone-decanoate","brandName":"nandrolone decanoate","genericName":"nandrolone decanoate","approvalYear":"1962","relationship":"same-target"},{"drugId":"prasterone","brandName":"prasterone","genericName":"prasterone","approvalYear":"","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT01466114","phase":"PHASE2","title":"Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition","status":"UNKNOWN","sponsor":"University of California, Los Angeles","startDate":"2011-10","conditions":["Relapsing-remitting Multiple Sclerosis","Secondary-progressive Multiple Sclerosis","Primary-progressive Multiple Sclerosis"],"enrollment":64,"completionDate":"2022-04"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"NDDF":"005975","UNII":"AS13K2DY03","CHEBI":"CHEBI:135790","INN_ID":"1558","RXNORM":"24416","UMLSCUI":"C0059648","ChEMBL_ID":"CHEMBL193482","PUBCHEM_CID":"10577","MESH_SUPPLEMENTAL_RECORD_UI":"C009341"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":39,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[{"date":"1995 May","pmid":"7641124","title":"Efficacy and safety of estriol replacement therapy for climacteric women.","journal":"Zhonghua yi xue za zhi = Chinese medical journal; Free China ed"},{"date":"1993","pmid":"7991851","title":"[Cytologic response of the irradiated vagina to estriol succinate].","journal":"Revista chilena de obstetricia y ginecologia"},{"date":"1990","pmid":"2346078","title":"The effect of peroral lynestrenol on serum lipids and lipoproteins in therapeutic amenorrhea of mentally retarded women.","journal":"Acta obstetricia et gynecologica Scandinavica"},{"date":"1987 Nov","pmid":"3428874","title":"Results of a 5 years prospective study of estriol succinate treatment in patients with climacteric complaints.","journal":"Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme"},{"date":"1983 Jan","pmid":"6832445","title":"The effect of oral estriol succinate therapy on the endometrial morphology in postmenopausal women: the significance of fractionation of the dose.","journal":"European journal of obstetrics, gynecology, and reproductive biology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Stiptanon, also known as estriol succinate, is a small molecule that targets the estrogen receptor beta. It is classified as an estriol succinate and its mechanism of action involves binding to estrogen receptors, specifically beta receptors. However, due to the lack of available information, its commercial status, approved indications, half-life, bioavailability, and generic manufacturers are unknown. As a result, its clinical use and safety profile are also unclear. Further research is needed to determine the potential benefits and risks of Stiptanon.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}